Veradermics, Incorporated research snapshot
MANE AI stock analysis currently reads Veradermics, Incorporated as a recently IPO-d clinical-stage biopharmaceutical company focused on dermatologic conditions, primarily pattern hair loss. At the July 12, 2026 data cutoff, MANE traded near $119.60 with a market capitalization of about $5.00 billion. The company has positive Phase II/III results for its lead candidate VDPHL01 (oral minoxidil for androgenetic alopecia), approximately $390.8 million in cash, no debt, and analyst price targets as high as $182. However, MANE has no approved products, negative earnings, a net loss of $98.8 million over the last twelve months, and binary pipeline risk that makes any forecast highly uncertain. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$119.60
Market cap
$5.00 billion
AI score
50 / 100
Rating
Speculative clinical-stage biotech with strong trial data but no approved revenue
Trend status
Strong uptrend following positive Phase II/III results, event-driven
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Veradermics is a pre-revenue clinical-stage biotech with one lead asset (VDPHL01 for hair loss) showing promising Phase II/III data. The business quality cannot be assessed on revenue or profit because no product is approved yet. | Low |
| Moat | The potential moat depends on VDPHL01 patent protection, regulatory approval, manufacturing scale, and commercial adoption. Oral minoxidil is not a new molecule, so differentiation hinges on formulation, delivery, safety profile, and IP that prevents generic competition. | Low-medium |
| Management | Management has guided VDPHL01 through positive Phase II/III trials and secured a public listing. Key questions remain about regulatory strategy, commercial execution, pipeline expansion beyond the lead asset, and capital allocation with limited financial resources. | Low-medium |
| Financial trend | MANE has no revenue, a trailing net loss of $98.8 million, cash of $390.8 million, and zero debt. The cash runway and burn rate are critical to track as the company moves toward regulatory filing and potential commercialization. | Medium |
| Valuation | At $119.60 and $5.00B market cap, MANE trades entirely on pipeline probability. Traditional P/E is not applicable. Price/Book of 12.79x is high but common for pre-revenue biotechs with positive data. Valuation depends on VDPHL01 approval probability, market size, pricing, and commercial execution. | Low |
| Technical trend | Strong uptrend with price up 262% year-to-date and near the upper end of the 52-week range. The stock is event-driven and can gap significantly on clinical, regulatory, or financing news. | Medium |
| Risk level | Risk is very high. Single-asset clinical-stage biotech with no revenue, binary regulatory outcomes, short trading history, potential dilution, and high volatility. The stock gained 262% YTD, which also means elevated expectations. | High |
| AI confidence | The descriptive clinical and cash position research is reasonably supported. Any forecast of future stock prices has very low confidence because a single FDA decision, trial result, or financing event can dominate all other factors. | Low |
| Investment certainty | Investment certainty is very low for a pre-revenue biotech with one lead asset, no matter how strong the clinical data. Position sizing should reflect the high probability of capital loss if VDPHL01 fails to reach the market. | Very low |
MANE AI stock forecast
The MANE AI stock forecast uses scenario ranges rather than a precise price prediction. Traditional valuation tools are not meaningful because MANE has no revenue or positive earnings. The forecast depends on VDPHL01 regulatory progress, potential partnership or financing events, competition in the hair loss market, and overall market appetite for biotech risk.
$160 to $200
More likely if Veradermics files for FDA approval by late 2026 or early 2027 with strong data, secures a partnership or licensing deal with a larger pharmaceutical company, demonstrates a clear commercial pathway for VDPHL01, and progresses pipeline candidates.
$90 to $140
More likely if the stock trades around current expectations while the market waits for the next major catalyst (FDA submission, clinical updates, or financing details) and pricing reflects normal biotech volatility between binary events.
$40 to $80
More likely if VDPHL01 faces regulatory delays, the FDA requires additional trials, safety concerns emerge from longer-term data, competition from existing hair loss treatments (finasteride, minoxidil, low-level laser therapy, or new entrants) limits commercial potential, or the company needs dilutive financing.
MANE AI technical analysis
MANE AI technical analysis starts from the $119.60 July 10, 2026 close and the after-hours level of $119.99. The stock has a very short public trading history (IPO in 2026) with a 52-week range of $32.00 to $131.24. Moving averages and momentum indicators should be confirmed in a live charting tool before use, as this static page does not fetch request-time data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $119.60 | Close on July 10, 2026. After-hours level was $119.99. |
| Near support | $105 to $115 | Estimated from recent trading range. A pullback to this zone would be a normal retracement in a strong uptrend. |
| Near resistance | $125 to $132 | The 52-week high is $131.24. A breakout above this level would signal continued momentum. |
| 50-day moving average | Requires live chart confirmation | The short trading history limits moving average reliability. Use current chart data before acting. |
| 200-day moving average | Requires live chart confirmation | Not meaningful with the stock only publicly traded since 2026. Use live data. |
| Momentum | Strong uptrend, event-driven | The stock has gained 262% YTD but momentum is highly dependent on clinical and regulatory news flow. |
| Volume | Moderate liquidity | Average volume of 659,259 shares. Volume can spike significantly around clinical data releases and news events. |
| Volatility | Very high | Pre-revenue biotech stocks regularly move 5-15% on clinical, regulatory, or financing news. Position sizing must account for this. |
| Invalidation | Close below $100 and further below $80 | A sustained break below $100 would weaken the short-term uptrend. A break below $80 would challenge the broader bullish thesis. |
MANE AI trading strategy
The MANE AI trading strategy is a rules-based framework for a speculative clinical-stage biotech stock. It is not personal advice and should be paired with live quotes, SEC filings, clinical trial calendars, FDA timelines, cash burn monitoring, and strict position sizing.
Consider MANE only if it holds above near support and confirms an uptrend with volume. Enter on pullbacks to support rather than chasing breakouts, given the high volatility.
A close below $100 or a failed breakout above $132 should trigger a review. Clinical or regulatory setbacks would invalidate the trend thesis entirely.
If MANE pulls back toward the $105 to $115 support zone without negative clinical news, compare the price action with the next expected catalyst and the latest financial disclosures.
Do not average down. Set a predefined maximum loss and honor it. Pre-revenue biotechs can decline 30-50% on bad data regardless of technical support.
Track the evidence that matters most for a clinical-stage dermatology biotech: VDPHL01 regulatory progress, safety updates, competitive landscape, cash runway, potential partnerships, and any pipeline diversification.
Reduce exposure if cash burn accelerates without clear milestones, if regulatory timelines slip, or if competitive threats emerge from existing or new hair loss treatments.
Investment research summary
Veradermics aims to develop and commercialize novel therapeutics for dermatologic and aesthetic conditions, with VDPHL01 (oral minoxidil) for pattern hair loss as the lead candidate. Customers would be patients and healthcare providers seeking an effective oral treatment for hair loss.
The potential moat depends on formulation IP, regulatory exclusivity, and commercial execution for VDPHL01. Oral minoxidil itself is not novel, so differentiation must come from improved safety, efficacy, convenience, or proprietary delivery that competitors cannot easily replicate.
The thesis fails if VDPHL01 does not receive FDA approval, if the required safety data package is more demanding than expected, if existing over-the-counter and prescription treatments maintain market dominance, if the company runs out of cash before reaching revenue, or if clinical data does not hold up under regulatory scrutiny.
Management successfully advanced VDPHL01 through Phase II/III trials and completed an IPO. The next test is regulatory strategy, preparing a commercial infrastructure, managing cash burn, and potentially expanding the pipeline beyond the lead asset.
The dermatology and aesthetic medicine market is large and growing, driven by aging populations, increased focus on appearance, and willingness to pay for treatments. Hair loss affects a significant portion of the population, creating a large addressable market if VDPHL01 gains approval.
With no revenue and negative EPS, traditional valuation metrics do not provide a margin of safety. The current $5.00B market cap prices in a significant probability of VDPHL01 approval and commercial success. The margin of safety improves only with clear regulatory progress, partnership validation, or demonstrated commercial demand.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MANE price | $119.60 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.00 billion, verified against public quote data | Yahoo Finance and public market data | July 12, 2026 |
| YTD return | +262.42% | Yahoo Finance performance data | July 12, 2026 |
| Cash and cash equivalents | $390.8 million | Yahoo Finance key statistics | July 12, 2026 |
| Total debt | None (0.00% Debt/Equity) | Yahoo Finance balance sheet data | July 12, 2026 |
| Net income (TTM) | -$98.8 million | Yahoo Finance financial data | July 12, 2026 |
| EPS (TTM) | -$2.64 | Yahoo Finance statistics | July 12, 2026 |
| Price/Book (mrq) | 12.79 | Yahoo Finance valuation measures | July 12, 2026 |
| 52-week range | $32.00 to $131.24 | Yahoo Finance quote data | July 12, 2026 |
| Average volume | 659,259 shares | Yahoo Finance quote data | July 12, 2026 |
| Analyst price target | $141.60 average, $182 high (Jefferies) | Yahoo Finance analyst insights | July 12, 2026 |
| Financial statement depth | Limited as recently IPO-d public company. Two-source cross-validation still needed before investment use. | Research quality check | July 12, 2026 |
This MANE AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, technical data, and third-party sources as of July 12, 2026. They may be wrong, incomplete, or outdated after new clinical data, FDA decisions, financing events, competitive developments, market moves, or macro conditions. Clinical-stage biotech investments carry a high risk of capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
